Background: Traditional risk factors used to assess cardiovascular risk miss a significant population who are indeed at risk for future cardiac events. Erectile dysfunction (ED) is an emerging marker for future cardiovascular disease (CVD) and major adverse cardiovascular events (MACE), especially in young and middle-aged men with vasculogenic ED. Cavernous arteries morphological alterations at penile colour doppler ultrasound (P-CDU) are used to find a vasculogenic ED. Objectives: We investigated the possible relationship between cavernous arteries morphological alterations at P-CDU assessment and future MACE. Materials and methods: We conducted a retrospective cohort study involving 300 ED patients, aged 35-65 years (mean age 54.1 AE 7.1), with a follow-up period of 10 years. Patients underwent vascular evaluation including P-CDU, colour doppler ultrasound of the carotid and lower limbs arteries. At baseline data for glucose metabolism, lipid profile, hypertension and hormonal status were collected. During the follow-up period, the occurrence of MACE was evaluated. Results: We found a strong association between cavernous arteries morphological alterations and CVD with a threefold increased risk of future MACE in comparison to patients with healthy cavernous arteries (RR 3.2,). This association remained statistically significant after adjustment for CV risk factors (age, glycaemia, total cholesterol, hypertension and smoke). Conclusions: Morphological alterations of cavernous arteries are independently associated with an increased risk of future MACE. These data contribute to the formulation of the hypothesis that cavernous artery pathology at P-CDU is related to MACE.
INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of global morbidity and mortality worldwide (Pagidipati & Gaziano, 2013) . Therefore, it is of great importance to identify, among the general population, those subjects at high cardiovascular risk and at early stage of CVD. Actually traditional cardiovascular risk factors evaluation fails to identify a proportion of apparently healthy men who are at risk for future cardiac events, especially among young adults (Clark et al., 2014) .
Many new biomarkers and associated conditions have been proposed as useful tools to detect early CVD and to stratify cardiovascular (CV) risk. Among associated conditions, erectile dysfunction (ED) is particularly interesting because it is currently accepted that it can be considered a sentinel symptom of subclinical CVD and an independent CV risk factor (Thompson et al., 2005) . ED of vascular origin (i.e. vasculogenic ED) is the more frequent subtype of ED reaching 70% of all cases (Lue, 1999) , and it might represent an early manifestation of generalized vascular disease. The pathophysiologic links between vascular ED and generalized vascular disease are well identified. The two processes share a number of upstream risk factors like glucose metabolism, dyslipidaemia, hypertension, obesity, tobacco use and sedentarism. These deleterious factors result in common underlying mechanism, among which inflammation, atherosclerosis and endothelial dysfunction are major contributors (Bivalacqua et al., 2003; Solomon et al., 2003; Fung et al., 2004; Grover et al., 2006; Hamilton & Watts, 2013) . At least four metaanalyses have confirmed the relationship between arteriogenic ED and CV risk (Dong et al., 2011; Yamada et al., 2012; Fan et al., 2018; Osondu et al., 2018) . All this evidence suggests that vasculogenic ED can be a harbinger for early CVD (Foresta et al., 2017; Uddin et al., 2018; Zhao & Zhang, 2018) . A recent study observed that the effect of ED on future coronary risk was strongly affected by patient age. Although ED had relatively little impact on the development of cardiac events in men aged 70 years or older, authors found that it resulted in a nearly 50-fold increase in the 10-year incidence density of heart disease in men aged 40 to 49 years. This observation suggests the possibility that ED, in young men, may be an early manifestation of a progressive systemic vasculopathy, preceding the development of coronary disease by decades (Inman et al., 2009) . These data are very intriguing considering that only lifestyle modification and CV risk factors optimization can improve ED and CV risk (Gupta et al., 2011; Allen & Walter, 2018; Sisti et al., 2018) .
The vascular origin of ED is usually diagnosed by dynamic penile colour doppler ultrasound (P-CDU) after intracavernosal PGE 1 injection. P-CDU assesses haemodynamic parameters and detects morphological alterations of cavernous arteries such as increased intima-media thickness (IMT) or the presence of atherosclerotic plaques (Caretta et al., 2006 (Caretta et al., , 2009 . Corona et al. (2008) previously demonstrated that the impairment of penile Doppler ultrasound is an independent risk factor for CVD. Conversely, as already recognized by the authors, no study has analysed the impact of penile artery morphology and forthcoming MACE.
In this study, we evaluated the contribution of cavernous arteries morphological alterations finding at P-DCU to the risk evaluation of subsequent MACE in a population of ED patients.
MATERIALS AND METHODS
We conducted a study involving 300 subjects referred for ED at the Unit of Andrology and Reproductive Medicine of the University of Padova between January 2006 and December 2011. Inclusion criteria were as follows: ED defined as IIEF-5 questionnaire < 22 and age between 35 and 65 years. Exclusion criteria were as follows: age <35 and >65 years, history of cardiovascular disease (IM, stroke, MACE and cardiac revascularization), end-stage renal disease or liver insufficiency. We also excluded patients with post-surgical ED and neoplastic and transplanted patients.
The calculation of the sample size (n = 300) was performed using the two-tailed long-rank test, setting at 85% (Ioakeimidis et al., 2016 ) the survival to major adverse cardiovascular events for subjects with ED and PSV>30 cm/sec vs. a 74% for subjects with PSV<30 cm/sec (HR:1.85) with (1Àb) = 80% and a = 5%.
Each patient underwent a complete medical history and physical examination. At baseline, glucose metabolism (fasting plasma glucose, glycated haemoglobin), serum lipid profile (total cholesterol, HDL-cholesterol and triglycerides), luteinizing hormone (LH), total testosterone and creatinine were measured. Blood collection and pressure measurement were performed in fasting condition, between 08.00 and 10.00 a.m., avoiding cigarette smoking for a minimum of 12 h.
Hypertension was defined as brachial systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg or ongoing antihypertensive medication. Diabetes mellitus was defined as two fasting plasma glucose ≥126 mg/dL and/or glycated haemoglobin ≥6.5% or use of antidiabetic therapy. Dyslipidaemia was defined as total cholesterol >200 mg/dL and/or triglycerides >150 mg/dL or use of lipid-lowering drug.
Patients underwent a vascular evaluation, including P-CDU, colour doppler ultrasound of the carotid arteries and of lower limbs. All colour doppler ultrasound was carried out by the same experienced operator (N.C.), with a high-resolution echo-colorDoppler (iU22 Philips, Eindhoven, The Netherlands or Aplio XV Toshiba, Tokyo, Japan) equipped with a 7-13 MHz probe (axial resolution <0.1 mm). For each carotid and femoral artery, three measurements of IMT (defined as the distance between the vessel lumen and the adventitia margin) were performed and the mean value of measurements carried out was considered as the m-IMT. P-CDU was performed after intracavernous injection of alprostadil 10 lg. Evaluation of intracavernous blood flow was assessed at the level of the peno-scrotal junction in the following 20 min as previously described (Caretta et al., 2006; Golijanin et al., 2007; Gupta et al., 2015) . PSV, end-diastolic velocity (EDV), resistance index (RI) and acceleration time (AccT) were measured. Cavernous intima-media thickness (IMT) was measured choosing the best rectilinear portion at low magnification. Afterwards, the selected portion was studied at high magnification (249 zoom), regulating the partial and total B-mode gain to reduce the noise at minimum level. A cavernous plaque was defined as an IMT >0.4 mm or a twofold thickening compared to the closest tracts. Cavernous artery alterations were subdivided into: (i) normal cavernous IMT (<0.3 mm); (ii) increased cavernous IMT (>0.3 and ≤0.4 mm); and (iii) cavernous plaque (IMT>0.4 mm) according to our previous published data (Caretta et al., 2009) . A 'healthy cavernous artery' was defined as the absence of any morphological alteration (i.e. neither increased IMT nor atherosclerotic plaque) in both cavernous arteries ( Fig. 1) .
Unfortunately, we have no data about patients coronary basal status (stress testing, coronary angiogram or coronary calcium score).
The follow-up period of 10 years and complete information were available for 254 patients. During the follow-up period, the occurrence of first MACE (myocardial infarction, hospitalization for unstable angina with or without revascularization, stroke and other cardiovascular events, such as lower limb revascularization), CVD death and all-cause death was recorded. Data collection was performed by a telephonic structured guided-interview to the patients.
Results are expressed as mean AE SD or percentage, according to the nature of the variable. Comparison between groups was performed with the Student t-test, using the Satterthwaite approximation if homoschedasticy was found. Association between categorical variables was assessed with the chi-square test. The analogue non-parametric version of the t-test and chisquare test was used whenever required by the non applicable conditions of the parametric test.
Regression analysis of survival data was based on the Cox proportional hazards model, using the PHREG procedure. Models were adjusted by age, glycemia, total cholesterol and smoking status.
Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA), and a p-value <0.05 was considered to be statistically significant.
The present study has been approved by the local ethics committee. All participants have been given details of the research and the possibility to ask any questions about the study. They had sufficient time to consider the invitation to participate, and have been informed that study participation was entirely optional. Table 1 shows the characteristics of the cohort at baseline (n = 254), and in patients with healthy (n = 170) or pathological (n = 84) cavernous arteries. Twenty-eight patients (11.0%) had PSV < 30 cm/sec: 21 (75.0%) in the group of men with pathological cavernous arteries and 7 (25.0%) in the group of men with healthy cavernous arteries.
RESULTS
During the follow-up period, there were four all-cause deaths and 35 patients had one or more MACE. Among these, 24 (9.4%) were myocardial infarction with coronary revascularization, four (1.6%) were stroke and 11 (4.3%) were other cardiovascular events (seven inferior limb revascularization intervention, two inferior limb amputation and two intervention for abdominal aorta aneurysm).
As shown in Table 2 , no difference was found in the incidence of death and MACE according to the presence or not of different pathological PSV cut-off (<25; <30 or <35 cm/sec). On the contrary, a finding of morphological alteration in at least one of the cavernous arteries was associated with a higher incidence of MACE and in particular of MI. The risk of having MACE was related to P-CDU findings. Pathological cavernous artery (increased cavernous IMT and /or plaque) was associated with a threefold increase in risk of future MACE (OR 3.25, 95% CI 1.63-6.49, p < 0.0001). The risk was also increased in men with vasculopathy at carotid and femoral districts (Table 3) .
Three statistical models to adjust these findings for age (model 1); age, glycaemia and total cholesterol (model 2); and age, glycaemia, hypertension, total cholesterol and smoking (model 3) were developed (Table 3) . Interestingly, the risk of MACE in pathological cavernous arteries remains statistically significant in all three statistical models. In general, the risk of MACE was 3.21 (95% CI 1.17-8.78) when a pathological cavernous artery was diagnosed at P-CDU.
Risk of MACE was 6.09 (95% CI 1.29-28.6) in less complicated patients when a pathological cavernous artery was diagnosed at P-CDU (Table 4) . Figure 2 shows the higher event-free survival of patients with healthy respect to those with pathological cavernous arteries along the follow-up period (Log-Rank test p = 0.0004).
DISCUSSION
In this study, we found a strong association between ED and CVD. In particular, ED is a predictor of future MACE when P-CDU showed pathological cavernous arteries (increased IMT and/or plaque). Vasculogenic ED in this cohort of young and middle-aged adults (35-65 years, mean age 54.1 AE 7.1) increased the risk of MACE by threefold, even after adjusting for confounding factors, and by sixfold in less complicated patients.
Erectile function is an haemodynamic phenomenon results from the interplay of neurological, endocrinological, tissutal, psychological, relational and vascular factors. In particular, endothelial-derived nitric oxide (NO) is probably the most important mediator of vasodilatation, and endothelial dysfunction, affecting NO release, is crucial to vasodilatation impairment in ED. Actually, ED is in 70% of cases of vascular origin (Bivalacqua et al., 2003) and may be initially a consequence of endothelial dysfunction. In fact, endothelial dysfunction is characterized by a reduced vasodilatation in response to stimuli, procoagulation, inflammation and arterial stiffness (Solomon et al., 2003) .
The vascular origin of ED is usually diagnosed by P-CDU after intracavernosal PGE 1 injection that assesses haemodynamics of blood flow and detects morphological alterations of cavernous arteries (IMT and/or plaques) (Caretta et al., 2009) .
Although it is now recognized that ED, and in particular vasculogenic ED, might precede clinical symptoms of CVD (Dong et al., 2011; Yamada et al., 2012; Fan et al., 2018; Osondu et al., 2018; Uddin et al., 2018) , the exact role of P-CDU parameters in estimating the future risk of CVD is not clear. Corona et al. (2008) previously demonstrated that the impairment of penile Doppler ultrasound is an independent risk factor for CVD. We have previously demonstrated that men with ED present an increased cavernous IMT than men without ED with the best IMT cut-off of 0.3 mm (sensitivity = 84% and specificity = 87%) (Caretta et al., 2009) .
Actually no study has analysed the impact of penile artery morphological alterations (cavernous IMT and plaque) and forthcoming MACE. Table 2 Incidence of death and MACE on the base of P-CDU findings Here, we showed that ED patients with cavernous vasculopathy (increased IMT and/or plaque) with respect to patients with healthy cavernous arteries are older, more frequently smokers, have a higher prevalence of diabetes mellitus and higher levels of fasting plasma glucose. More importantly, ED subjects with pathological cavernous arteries showed signs of vascular impairment also in other vascular districts such as carotid and femoral arteries, confirming previous studies of our group (Foresta et al., 2008) . These differences between ED patients with healthy vs pathological cavernous arteries were confirmed at follow-up, where the incidence of MACE significantly differed between the two groups. In other words, these data showed that it is not ED per se but vasculogenic ED with morphological alterations of the cavernous arteries that is associated with increased risk of future MACE.
In order to investigate the contribution of vasculogenic ED above and beyond traditional risk factors in predicting future MACE, we developed statistical models that adjusted the risk for known CVD risk factors (age, glucose plasma levels, hypertension, total cholesterol and smoking). This analysis showed that cavernous vasculopathy increased the risk by threefold independently from classic cardiovascular risk factors. Vlachopoulos et al. have documented that the clinical significance of ED in predicting MACE is higher in less complicated subjects. Therefore, we analysed our data excluding step by step subjects with diabetes, hypertension and dyslipidaemia at baseline showing that in less complicated patients cavernous vasculopathy increased the risk by sixfold.
Some other studies have already reported a link between P-CDU assessment of haemodynamic parameters and cardiovascular disease. For example, in a small prospective study involving 49 men with vascular ED, cavernosal artery insufficiency defined as PSV <30 cm/sec was predictor of abnormal stress echocardiogram (Mulhall et al., 2009) . Another study on a total of 2396 patients with a longitudinal follow-up, on 1687 of them found that vascular ED (as suggested by an incomplete response to vasodilatory medications administered during P-CDU) was predictive for hypogonadal symptoms, diabetes, metabolic syndrome and MACE (Rastrelli et al., 2011) .
One of the strengths of the present study is the analysis of the different vascular parameters obtained by P-CDU beyond classic PSV. PSV is generally used to define ED as due to vascular impairment (Ioakeimidis et al., 2016) but we found no association between isolated pathological PSV (<25 or <30 or <35 cm/sec) and MACE occurrence. Although this is in contrast with results of other studies, we could speculate on this finding. In fact, we found that morphological alterations in cavernous arteries (increased IMT and/or plaque) represent a better risk marker than PSV in predicting MACE. Possible explanations might be multiple. As described by Pagano and Stahl (2015) , the location of cavernous artery imaging appears to have a significant effect on the resulting measurement with more proximal measurements being significantly higher than those taken more distally. P-DCU performed using alprostadil (PGE 1 ) probes the adenylated cyclase -cAMP pathway to induce erection and this is somehow independent from the endothelium mediated NO production. Moreover, the stimulation used during P-DCU is supraphysiological in dose and this may mask mild defects and early impairment. On the contrary, morphological changes in cavernous arteries are indeed associated with endothelial dysfunction (Shah et al., 2016) , which define the presence of a systemic functional impairment at the very early stage.
Taken altogether, these findings suggest a great value of morphological P-CDU data in the evaluation of ED, because it is crucial in defining the ED subtype (i.e. identifying vascular ED). Furthermore it can provide data with a more significant impact in stratifying the cardiovascular risk of ED patients respect to carotid or femoral vasculopathy. From a clinical point of view, the identification of cavernous vasculopathy with P-CDU implies full cardiovascular evaluation of the ED patients as recently suggested by some authors (Fung et al., 2004; Miner et al., 2014; Shah et al., 2016) .
Considering the low number of patients studied, the lack of data about coronary artery status at baseline and the lack of inter-observer variability evaluation, further studies will be necessary to confirm these data. Furthermore, performing P-CDU with 15-22 mHz probes will allow better resolution and more precise measurement of cavernous artery IMT.
CONCLUSION
In this study, cavernous vasculopathy is independently associated with an increased risk of future MACE in ED middle-aged patients with greater evidence in less complicated subjects. These data contribute to the formulation of the hypothesis that cavernous artery pathology at P-CDU is related to MACE.
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